Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Preclinical Findings with its IMGN289 Product Candidate for the Treatment of EGFR-Overexpressing Cancers
Novel antibody-drug conjugate (ADC) can kill Epidermal Growth Factor Receptor (EGFR)-overexpressing cancer cells via two mechanisms — EGFR-inhibition and direct cell-killing. In preclinical testing, IMGN289 was highly active against EGFR-overexpressing cancer cells, including those not dependent on
View HTML
Toggle Summary Webcast of the ImmunoGen, Inc. Analyst and Investor Community Meeting on April 12, 2013
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics, today announced that investors, journalists and the general public are invited to listen to a live webcast of the Company's analyst and investor community meeting on
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2013 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 26, 2013 , to discuss ImmunoGen's financial results for the
View HTML
Toggle Summary ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
First product with ImmunoGen's ADC technology, Kadcyla™, launched in the US. Multiple additional markets, indications expected. Three novel wholly owned ImmunoGen compounds advancing in clinical testing, with the first clinical data for IMGN853 to be reported at ASCO.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate (ADC) technology, today announced that Gregory Perry , Executive Vice President and Chief Financial
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming
View HTML
Toggle Summary First Clinical Data Presented with IMGN853, ImmunoGen, Inc.'s Potential New Therapy for Ovarian and Other Cancers
First clinical findings presented with ImmunoGen's folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), IMGN853. Preliminary evidence of activity seen in dose-finding portion of trial. WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2013 Financial Results
— Webcast of presentation at upcoming investor conference also announced — WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate technology, today announced
View HTML
Toggle Summary ImmunoGen, Inc. Announces FDA Acceptance of IND for Company's Novel EGFR-Targeting ADC, IMGN289
Novel antibody-drug conjugate (ADC) IMGN289 on track to begin human clinical testing for treatment of EGFR-positive tumors in 4Q2013. IMGN289 is a potential new treatment for lung, head and neck, and other EGFR-positive solid tumors, including ones not effectively treated with EGFR-directed
View HTML
Toggle Summary ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
Kadcyla ® sales off to strong start. Decision on approval in European Union , TH3RESA Phase III data presentation expected by Roche in 2H2013. ImmunoGen progress with its proprietary pipeline includes advancement of third wholly owned product candidate for solid tumors, IMGN289, to active IND and
View HTML